Zymeworks Inc. (ZYME)
NYSE$12.52
Market Cap
$871.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
6 of 883
Rank in Industry
5 of 510
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $50M |
ZYME Insider Trading Activity
ZYME Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $57,400,468 | 34 | 92 |
Sells | $1,337,214 | 3 | 8 |
Related Transactions
| EcoR1 Capital, LLC | 34 | $57.4M | 0 | $0 | $57.4M | |
| Smith Jeffrey T L | EVP & Chief Medical Officer | 0 | $0 | 1 | $165,807 | $-165,807 |
| Moore Paul Andrew | Chief Scientific Officer | 0 | $0 | 1 | $316,391 | $-316,391 |
| Galbraith Kenneth | Chair & CEO | 0 | $0 | 1 | $855,017 | $-855,017 |
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or …
Insider Activity of Zymeworks Inc.
Over the last 12 months, insiders at Zymeworks Inc. have bought $57.4M and sold $1.34M worth of Zymeworks Inc. stock.
On average, over the past 5 years, insiders at Zymeworks Inc. have bought $26.75M and sold $2.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC () — $57.4M.
The last purchase of 54,760 shares for transaction amount of $630,819 was made by EcoR1 Capital, LLC () on 2025‑04‑17.
List of Insider Buy and Sell Transactions, Zymeworks Inc.
| 2025-04-17 | EcoR1 Capital, LLC | 54,760 0.0869% | $11.52 | $630,819 | +7.03% | |||
| 2025-04-16 | EcoR1 Capital, LLC | 73,953 0.1138% | $11.16 | $825,589 | +9.61% | |||
| 2025-04-04 | EcoR1 Capital, LLC | 196,438 0.288% | $11.17 | $2.19M | -2.66% | |||
| 2025-04-03 | EcoR1 Capital, LLC | 120,770 0.1749% | $11.84 | $1.43M | -5.64% | |||
| 2025-04-02 | EcoR1 Capital, LLC | 74,360 0.1062% | $11.85 | $881,017 | -5.54% | |||
| 2025-04-01 | EcoR1 Capital, LLC | 48,658 0.0698% | $11.60 | $564,647 | -3.01% | |||
| 2025-03-31 | EcoR1 Capital, LLC | 4,397 0.0062% | $11.75 | $51,658 | -5.37% | |||
| 2025-03-26 | EcoR1 Capital, LLC | 43,848 0.0625% | $12.24 | $536,857 | -6.76% | |||
| 2025-03-25 | EcoR1 Capital, LLC | 53,501 0.0775% | $12.91 | $690,452 | -9.22% | |||
| 2025-03-24 | EcoR1 Capital, LLC | 22,689 0.0327% | $13.08 | $296,847 | -10.33% | |||
| 2025-03-21 | EcoR1 Capital, LLC | 31,033 0.0448% | $12.78 | $396,518 | -7.35% | |||
| 2025-03-20 | EcoR1 Capital, LLC | 73,476 0.1056% | $12.93 | $949,883 | -8.53% | |||
| 2025-03-19 | EcoR1 Capital, LLC | 58,306 0.0828% | $12.64 | $737,233 | -7.19% | |||
| 2025-03-18 | EcoR1 Capital, LLC | 113,880 0.1678% | $12.65 | $1.44M | -3.61% | |||
| 2025-03-17 | EcoR1 Capital, LLC | 56,277 0.0787% | $12.23 | $688,465 | -5.10% | |||
| 2025-03-13 | EcoR1 Capital, LLC | 468,356 0.6696% | $12.48 | $5.85M | -4.87% | |||
| 2025-03-12 | EcoR1 Capital, LLC | 292,934 0.4199% | $12.25 | $3.59M | -2.46% | |||
| 2025-03-11 | EcoR1 Capital, LLC | 320,690 0.4528% | $11.49 | $3.69M | +2.86% | |||
| 2025-01-17 | EcoR1 Capital, LLC | 19,748 0.0286% | $13.87 | $273,998 | -8.00% | |||
| 2025-01-16 | EcoR1 Capital, LLC | 121,681 0.1755% | $13.88 | $1.69M | -8.58% |
Total: 96
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| EcoR1 Capital, LLC | 17828487 25.6241% | $223.21M | 43 | 0 | <0.0001% | |
| Redmile Group, LLC | 10 percent owner | 6075918 8.7327% | $76.07M | 1 | 0 | +63.8% |
| Tehrani Ali | Chief Executive Officer | 260325 0.3742% | $3.26M | 1 | 6 | +12.44% |
| Josephson Neil | Chief Medical Officer | 14449 0.0208% | $180,901.48 | 1 | 1 | <0.0001% |
| Cox Troy | director | 7500 0.0108% | $93,900.00 | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$571,084,134 | 44 | 4.33% | $890.12M | |
$97,176 | 41 | 42.84% | $803.86M | |
$28,907,358 | 35 | 41.41% | $763.81M | |
$309,951,506 | 30 | 32.56% | $1.01B | |
$7,598,498 | 27 | 34.68% | $1B |
ZYME Institutional Investors: Active Positions
| Increased Positions | 80 | +39.8% | 5M | +7.7% |
| Decreased Positions | 85 | -42.29% | 6M | -8.69% |
| New Positions | 33 | New | 2M | New |
| Sold Out Positions | 22 | Sold Out | 1M | Sold Out |
| Total Postitions | 196 | -2.49% | 66M | -0.99% |
ZYME Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ecor1 Capital, Llc | $173,274.00 | 21.47% | 15.03M | +2M | +11.84% | 2024-12-31 |
| Redmile Group, Llc | $55,811.00 | 6.92% | 4.84M | -261,448 | -5.13% | 2024-12-31 |
| Bvf Inc/Il | $49,682.00 | 6.16% | 4.31M | -299,000 | -6.49% | 2024-12-31 |
| Morgan Stanley | $48,443.00 | 6% | 4.2M | -905,432 | -17.73% | 2024-12-31 |
| Blackrock, Inc. | $48,253.00 | 5.98% | 4.18M | -78,639 | -1.84% | 2024-12-31 |
| Rubric Capital Management Lp | $45,167.00 | 5.6% | 3.92M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $28,748.00 | 3.56% | 2.49M | -365,226 | -12.78% | 2024-12-31 |
| Bnp Paribas Asset Management Holding S.A. | $24,647.00 | 3.05% | 2.14M | +192,162 | +9.88% | 2024-12-31 |
| Perceptive Advisors Llc | $24,559.00 | 3.04% | 2.13M | -50,000 | -2.29% | 2024-12-31 |
| Deutsche Bank Ag | $17,834.00 | 2.21% | 1.55M | +17,849 | +1.17% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.